| 000 | 01747 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516232605.0 | ||
| 264 | 0 | _c20150803 | |
| 008 | 201508s 0 0 eng d | ||
| 022 | _a1098-6596 | ||
| 024 | 7 |
_a10.1128/AAC.03777-14 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDolton, Michael J | |
| 245 | 0 | 0 |
_aUnderstanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _cNov 2014 |
||
| 300 |
_a6879-85 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xpharmacology |
| 650 | 0 | 4 |
_aAnticonvulsants _xpharmacology |
| 650 | 0 | 4 |
_aAntiemetics _xpharmacology |
| 650 | 0 | 4 |
_aAntifungal Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 |
_aCarbamates _xpharmacology |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aDrug Therapy, Combination _xadverse effects |
| 650 | 0 | 4 | _aFurans |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMetoclopramide _xpharmacology |
| 650 | 0 | 4 |
_aNucleic Acid Synthesis Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aOrganophosphates _xpharmacology |
| 650 | 0 | 4 |
_aPhenytoin _xpharmacology |
| 650 | 0 | 4 |
_aProton Pump Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aRifampin _xpharmacology |
| 650 | 0 | 4 |
_aSulfonamides _xpharmacology |
| 650 | 0 | 4 |
_aTriazoles _xadverse effects |
| 700 | 1 | _aBrüggemann, Roger J M | |
| 700 | 1 | _aBurger, David M | |
| 700 | 1 | _aMcLachlan, Andrew J | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 58 _gno. 11 _gp. 6879-85 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.03777-14 _zAvailable from publisher's website |
| 999 |
_c24170080 _d24170080 |
||